Read by QxMD icon Read

Future Oncology

Martin Reck, Keith M Kerr, Christian Grohé, Christian Manegold, Nick Pavlakis, Luis Paz-Ares, Rudolf M Huber, Sanjay Popat, Nick Thatcher, Keunchil Park, Frank Hilberg, José Barrueco, Rolf Kaiser
A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has 'aggressive disease', as reflected in short time to progression or lack of disease control with initial platinum-based chemotherapy. Recently, clinical correlates of aggressive disease behavior during first-line therapy have been shown to predict greater benefit from addition of nintedanib to second-line docetaxel in adenocarcinoma NSCLC. Positive predictive effects of aggressive disease have since been reported with other anti-angiogenic agents (ramucirumab and bevacizumab), while such features may negatively impact on outcomes with nivolumab in nonsquamous NSCLC with low programmed death-ligand 1 expression...
February 13, 2019: Future Oncology
Jing Luo, Bowei Zhang, Likun Cui, Tong Liu, Yi Gu
AIM:  To examine the expression profile of FMO1 in papillary thyroid cancer (PTC) and its prognostic value in recurrence-free survival (RFS). METHODS:  A retrospective analysis was performed using data from the Cancer Genome Atlas and Human Protein Atlas. RESULTS: The most frequent variants of PTC had decreased FMO1 expression compared with their respective adjacent normal tissues. However, even under the best cutoff model, high FMO1 expression was only significantly associated with better RFS in classical PTC (p < 0...
February 13, 2019: Future Oncology
Vicki A Morrison, Yaping Shou, Jill A Bell, Laurie Hamilton, Augustina Ogbonnaya, Aditya Raju, Kristin Hennenfent, Michael Eaddy, Aaron Galaznik
AIM: To evaluate treatment patterns of diffuse large B-cell lymphoma (DLBCL). PATIENTS & METHODS: First-line and relapsed/refractory treatment patterns and survival outcomes following first-line therapy in adult patients newly diagnosed with DLBCL were evaluated. RESULTS: A total of 1436 DLBCL patients initiated treatment and mainly received a combination regimen versus monotherapy (92.1 vs 7.9%). Patients who received monotherapy were older with more comorbidities and had shorter progression-free survival than patients receiving combination therapy (median, 31...
February 13, 2019: Future Oncology
Guijiang Sun, Xuanrong Chen, Ue Gong, Yawei Chen, Guilai Li, Fang Wei, Aili Jiang, Yuanjie Niu, Zhiqun Shang
Patients with metastasis prostate cancer underwent androgen deprivation therapy (ADT) in the considering of the leading role of androgen receptor pathway. However, the resistance occurred within 1 year or more. The combination of cytotoxic chemotherapy and abiraterone for ADT therapy was performed in recent randomized controlled trials. The meta-analysis was focused on the treatment comparisons between additional treatment with ADT and ADT alone. A significant difference was observed that the overall survival benefit of early and active additional treatment with ADT in patients with hormone-sensitive metastatic prostate cancer...
February 11, 2019: Future Oncology
Ken Kato, Manish A Shah, Peter Enzinger, Jaafar Bennouna, Lin Shen, Antoine Adenis, Jong-Mu Sun, Byoung Chul Cho, Mustafa Özgüroğlu, Takashi Kojima, Vladimir Kostorov, Cinta Hierro, Ying Zhu, Lee Anne McLean, Sukrut Shah, Toshihiko Doi
BACKGROUND: Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. AIM: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer...
February 8, 2019: Future Oncology
Vijay N Joish, Sandip Shah, Jonothan C Tierce, Deep Patel, Chad McKee, Pablo Lapuerta, Jerome Zacks
AIM: Elevated serotonin in patients with neuroendocrine tumors (NETs) may impact heart failure incidence but a quantitative relationship has not been established. MATERIALS & METHODS: Systematic review and meta-analysis of studies assessing 24-h urinary 5-hydroxyindoleacetic acid (u5-HIAA) and mortality in patients with NETs (2007-2017) with a primary outcome of 1-year mortality risk and 24-h u5-HIAA. RESULTS: We identified 1715 records of which 12 studies including 755 patients (3442 person-years with 376 deaths) were eligible for meta-analysis...
February 8, 2019: Future Oncology
Pieternella J Lugtenburg, Alexander R Lyon, Reinhard Marks, Stefano Luminari
The decisive factor in selecting a treatment regimen for a frail patient with aggressive non-Hodgkin's lymphoma is identifying whether a patient is fit enough to tolerate curative-intent anthracycline-containing regimens or too frail and therefore at risk of being undertreated. As cardiac comorbidities are an important contributor to both the health status and the selection of treatment, cardiovascular profiling and baseline risk stratification prior to treatment should be considered. Comprehensive geriatric assessment is an efficient means of identifying elderly patients with non-Hodgkin's lymphoma who may benefit from a curative treatment approach...
February 7, 2019: Future Oncology
Toni Leigh Mortimer, Tom Mabin, Anna-Mart Engelbrecht
Despite remaining one of the most widely abused drugs worldwide, Cannabis sativa exhibits remarkable medicinal properties. The phytocannabinoids, cannabidiol and Δ-9-tetrahydrocannabinol, reduce nausea and vomiting, particularly during chemotherapy. This is attributed to their ability to reduce the release of serotonin from enterochromaffin cells in the small intestine, which would otherwise orchestrate the vomiting reflex. Although there are many preclinical and clinical studies on the effects of Δ-9-tetrahydrocannabinol during nausea and vomiting, little is known about the role that cannabidiol plays in this scenario...
February 5, 2019: Future Oncology
Abdalla Aly, Ruchitbhai Shah, Kala Hill, Marc F Botteman
AIM: This analysis estimated the overall survival, treatment patterns and economic burden of elderly metastatic triple-negative breast cancer patients. MATERIALS & METHODS: Patients (≥66 years) with metastatic triple-negative breast cancer were identified from the SEER-Medicare database. Treatment patterns were defined in terms of first, second and third or more regimens. Healthcare resource use and costs were reported over the follow-up period and over the treatment duration of each regimen...
February 5, 2019: Future Oncology
Beili Wang, Feng Li, Luya Cheng, Yanxia Zhan, Boting Wu, Pu Chen, Junfei Shen, Wenhao Wu, Xiaolu Ma, Jie Zhu, Baishen Pan, Wei Guo, Yunfeng Cheng
AIM: To explore the prognostic value of the pretreatment platelet (PLT) count in patients undergoing transcatheter arterial chemoembolization (TACE) with hepatocellular carcinoma (HCC). MATERIALS & METHODS: We prospectively analyzed 317 hepatitis B virus-related HCC patients undergoing TACE. Time to progression (TTP) was selected to evaluate the clinical significance of PLT level in HCC patients. RESULTS: PLT was the only parameter showing statistical significance of all the clinical characteristics between two distinct tumor response groups...
February 4, 2019: Future Oncology
Juan W Valle, Ivan Borbath, Brad Rosbrook, Kathrine Fernandez, Eric Raymond
AIM: To describe the long-term safety of sunitinib in patients with progressive, well-differentiated, advanced/metastatic pancreatic neuroendocrine tumors. PATIENTS & METHODS: Sunitinib- and placebo-treated patients from the Phase III study continued to receive sunitinib (37.5 mg on a continuous daily-dosing regimen) in two open-label extension studies. RESULTS: Median (range) treatment exposure: 30.2 (0.7-269.4) and 87.1 (3.9-319.4) weeks for medium-term (n = 41) and long-term-treated (n = 61) populations, respectively...
January 31, 2019: Future Oncology
Carol Mansfield, Briana Ndife, Joyce Chen, Kathleen Gallaher, Sameer Ghate
AIM: To investigate patient preferences for clinical attributes of first-line metastatic melanoma treatments. MATERIALS & METHODS: A discrete-choice experiment and best-worst scaling exercise were used to assess relative preferences for treatment attributes. RESULTS: The 200 survey respondents had distinct preferences. Avoiding a 30% risk of colitis or hormone gland problems and avoiding severe fever were more important to respondents than avoiding a 20% risk of extreme sun sensitivity (p < 0...
January 29, 2019: Future Oncology
Ramon Andrade De Mello, Inês Faleiro, Joana D Apolónio, Uri Tabori, Aryeh J Price, Vânia P Roberto, Pedro Castelo-Branco
No abstract text is available yet for this article.
January 29, 2019: Future Oncology
Pingping Hu, Qiqi Liu, Guodong Deng, Jingxin Zhang, Ning Liang, Jian Xie, Jiandong Zhang
AIM: To evaluate the prediction ability of neutrophils and develop a nomogram on radiosensitivity in thoracic cancer patients. METHODS: We retrospectively reviewed 398 lung and esophageal cancers patients who received external-beam radiotherapy or concurrent chemoradiotherapy as first-line therapy. RESULTS: Logistic regression model showed that patients with low levels of neutrophil counts and/or TGF-β1 exhibited better radiation sensitivity...
January 29, 2019: Future Oncology
John T Vetto, Eddy C Hsueh, Brian R Gastman, Larry D Dillon, Federico A Monzon, Robert W Cook, Jennifer Keller, Xin Huang, Andrew Fleming, Preston Hewgley, Pedram Gerami, Sancy Leachman, Jeffrey D Wayne, Adam C Berger, Martin D Fleming
AIM: Can gene expression profiling be used to identify patients with T1-T2 melanoma at low risk for sentinel lymph node (SLN) positivity? PATIENTS & METHODS: Bioinformatics modeling determined a population in which a 31-gene expression profile test predicted <5% SLN positivity. Multicenter, prospectively-tested (n = 1421) and retrospective (n = 690) cohorts were used for validation and outcomes, respectively. RESULTS: Patients 55-64 years and ≥65 years with a class 1A (low-risk) profile had SLN positivity rates of 4...
January 29, 2019: Future Oncology
Viktor Grünwald, Thomas Powles, Toni K Choueiri, Thomas E Hutson, Camillo Porta, Masatoshi Eto, Cora N Sternberg, Sun Young Rha, Cixin S He, Corina E Dutcus, Alan Smith, Lea Dutta, Kalgi Mody, Robert J Motzer
AIM: Lenvatinib plus everolimus is approved for the treatment of advanced renal cell carcinoma (RCC) after one prior vascular endothelial growth factor-targeted therapy. Lenvatinib plus pembrolizumab demonstrated promising antitumor activity in a Phase I/II trial of RCC. METHODS: We describe the rationale and design of the CLEAR study, a three-arm Phase III trial comparing lenvatinib plus everolimus and lenvatinib plus pembrolizumab versus sunitinib monotherapy for first-line treatment of RCC...
January 28, 2019: Future Oncology
Maria Ida Abbate, Diego Luigi Cortinovis, Marcello Tiseo, Tiziana Vavalà, Giulio Cerea, Luca Toschi, Stefania Canova, Francesca Colonese, Paolo Bidoli
AIM: We investigated outcomes in patients with advanced non-small-cell lung cancer (NSCLC) and peritoneal involvement. PATIENTS & METHODS: NSCLC patients with peritoneal carcinomatosis (PC) were included. We evaluated mOS1 (overall survival [OS] from NSCLC diagnosis) and mOS2 (OS from diagnosis of PC). RESULTS: In total, 60 NSCLC patients were diagnosed with PC, 12 (20%) patients had a diagnosis of NSCLC and synchronous PC with a median OS of 9 months...
January 25, 2019: Future Oncology
Shailesh M Gondivkar, Rahul R Bhowate, Amol R Gadbail, Rima S Gondivkar, Sachin C Sarode
AIM: The purpose of this study was to analyze the impact of socioeconomic characteristics on oral health-related quality of life (OHRQoL) in patients with oral submucous fibrosis (OSF). METHODS:  A total of 300 OSF patients' quality of life (QoL) data were obtained using OHRQoL-OSF and global self ratings of oral health and overall wellbeing. The socioeconomic status (SES) of participants was analyzed by using modified Kuppuswamy scale. RESULTS: OSF patients with lower SES had worse OHRQoL as compared with those with middle and upper SES (p < 0...
January 23, 2019: Future Oncology
Elie El Rassy, Tarek Assi, Ziad Bakouny, Fadi El Karak, Nicholas Pavlidis, Marwan Ghosn
AIM: The literature lacks direct evidence comparing the different regimens evaluated in the second-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). METHODS: We conducted a network meta-analysis (NMA) of the randomized controlled phase reporting on the second-line drug therapy in R/M SCCHN. RESULTS: These eligible trials included 11 regimens among which six targeted therapies, two immune checkpoint inhibitors and three chemotherapy drugs...
January 23, 2019: Future Oncology
Tao Lv, Yujie Wang, Xiaoshen Wang
AIM: To analyze the prognostic factors and the impact of postoperative radiotherapy (PORT) in parotid gland infiltrating ductal carcinoma (IDC). MATERIALS & METHODS: 252 patients diagnosed with parotid gland IDC were identified from the SEER database. Kaplan-Meier and Cox regression analysis was performed to evaluate the prognostic factors. Propensity score matching was applied then. RESULTS: Multivariate analysis showed old age and chemotherapy were independent risk factors in parotid gland IDC...
January 22, 2019: Future Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"